Start up. Grow up. Succeed.

News 2019

Immunic Therapeutics and Vital Therapies Complete Transaction Creating Nasdaq-Listed Company Targeting Chronic Inflammatory and Autoimmune Diseases

Developing Oral Therapies with Best-in-Class Potential Lead Program, IMU-838, Already Advanced into Phase 2 Studies in Ulcerative Colitis and Relapsing-Remitting Multiple Sclerosis Proceeds of approximately USD 30 million from concurrent financing to fund ...

BioNTech Congratulates CEO and Co-founder Prof. Ugur Sahin on German Cancer Award 2019

Mainz, Germany, February 28, 2019 – BioNTech AG, a rapidly growing biotechnology company developing precise and individualized immunotherapies for the treatment of cancer and the prevention of infectious diseases, congratulates its Co-founder and CEO Pro...

Immunic Therapeutics Announces First Patient Enrolled in Phase 2 Clinical Trial of IMU-838, an Oral Therapy for Patients with Relapsing- Remitting Multiple Sclerosis

Planegg-Martinsried, Germany, February 26, 2019 – Immunic AG (Immunic), a privately held clinicalstage biotechnology company, today announced enrollment of the first patient in a phase 2 clinical study of IMU-838 for the treatment of patients with relaps...

BioNTech to Acquire Antibody Generation Unit of MAB Discovery

Mainz and Munich, Germany, January 23, 2019 – BioNTech AG, a rapidly growing biotechnology company developing precise and individualized immunotherapies for the treatment of cancer and the prevention of infectious diseases, and MAB Discovery GmbH, a uniq...

Vital Therapies and Immunic Therapeutics Announce Transaction to Create Leading Inflammatory and Autoimmune Disease Company

Transaction Expected to Create NASDAQ-listed Biopharmaceutical Company Focused on Advancing Immunic‘s Compelling Pipeline of Clinical-Stage and Late Preclinical Assets Lead Program, IMU-838, an Orally Available, Small Molecule Inhibitor of DHODH, Alre...

AYOXXA signs research agreement in the field of ophthalmology with one of the leading pharmaceutical companies

Agreement targets the development of low volume and high sensitivity multiplex assays for aqueous humor protein profiling for biomarker identification and validation in support of drug discovery in ophthalmology This collaboration reflects an initial ...

Sanofi Invests EUR 80m (approx. USD 91.5m) in BioNTech as Partners Extend Collaboration and Advance mRNA-based Cancer Immunotherapy into Clinical Testing against Multiple Solid Tumors

Mainz, Germany, January 04, 2019 – BioNTech AG, a rapidly growing biotechnology company developing precise and individualized immunotherapies for the treatment of cancer and the prevention of infectious diseases, today announced that it has extended its ...